Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Short-term Investments (2023 - 2025)

Compass Therapeutics (CMPX) has disclosed Short-term Investments for 3 consecutive years, with $178.3 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments rose 114.16% to $178.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $178.3 million through Dec 2025, up 114.16% year-over-year, with the annual reading at $178.3 million for FY2025, 114.16% up from the prior year.
  • Short-term Investments hit $178.3 million in Q4 2025 for Compass Therapeutics, up from $173.7 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $178.3 million in Q4 2025 to a low of $71.6 million in Q1 2025.
  • Historically, Short-term Investments has averaged $125.2 million across 3 years, with a median of $130.4 million in 2023.
  • Biggest YoY gain for Short-term Investments was 114.16% in 2025; the steepest drop was 46.01% in 2025.
  • Year by year, Short-term Investments stood at $128.2 million in 2023, then tumbled by 35.09% to $83.2 million in 2024, then soared by 114.16% to $178.3 million in 2025.
  • Business Quant data shows Short-term Investments for CMPX at $178.3 million in Q4 2025, $173.7 million in Q3 2025, and $78.1 million in Q2 2025.